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Prostate cancer (PCa) is the secondmost common cancer inmen. Aswell inmany other human cancers, inflammation and immune
suppression have an important role in their development. We briefly describe the host components that interact with the tumor to
generate an immune suppressive environment involved in PCa promotion and progression. Different tools provide to overcome the
mechanisms of immunosuppression including vaccines and immune checkpoint blockades. With regard to this, we report results
of most recent clinical trials investigating immunotherapy in metastatic PCa (Sipuleucel-T, ipilimumab, tasquinimod, Prostvac-VF,
and GVAX) and provide possible future perspectives combining the immunotherapy to the traditional therapies.
1. Introduction
Prostate cancer (PCa) is the second most common cancer in
men. Although an estimated 15% of the cancers occurred in
men in most developed countries, incidence rates are also
relatively high in certain less developed regions. It represents
the fifth leading cause of death from cancer inmen [1].There-
fore screening and management of early prostate cancer are
critical medical challenges. Even though the precise aetiology
is not completely defined, both hereditary and environmental
factors are important in the development of PCa. Human and
animal studies suggest that the inflammation and the elusion
of immune destruction can have an important role in PCa as
well in the development of many other human cancers [2].
Immune evasion is now recognized as a hallmark feature of
cancer [3].
Generally the inflammatory process restores the home-
ostasis but especially the chronic inflammation can produce
a microenvironment that supports cancer initiation and pro-
gression [4, 5]. In addition to this extrinsic pathway, genetic
alterations leading to cancer can also stimulate the inflam-
matory process, thus contributing to the establishment of a
microenvironment favorable to tumor progression (Figure 1)
[4]. Recent studies have demonstrated that the interaction
between immune system inflammation and cancer is very
complex and still far from fully understood, ranging from
positive local effects, such as cytotoxicity mediated by T-cells
to tumor progression until the destructive systemic effects
such as cachexia [6].
In cancer patients immunity system is often altered with
an excess of inhibitory functions induced by regulatoryT cells
(Treg) or myeloid-derived suppressor cells (MDSC) and by
secretion of the immunosuppressive cytokines, tumor growth
factor (TGF)-𝛽, and interleukin (IL)-10. The manipulation of
the immune system is also one of new promising therapies
for cancer treatment, as detected in many different tumors
(colon, breast, melanoma, and prostate) but until now only
rarely established durable effects have been demonstrated
[7]. Several ongoing trials have the purpose to identify new
therapies that interfere with synergic activity of immunosup-
pressive environment and restore immune competence.
The aim of this review is to describe some of the
agents that can activate different pathways involved in PCa
promotion and progression, with particular interest to those
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Figure 1:MDSCs produce high amount of IL-10 and drive polarized
macrophage M2 (TAM) and active Tregs. MDSCs, TAMs, and Treg
produce a cytokine subsets that interfere with DCs differentiation
and enhance the suppressive phenotype of each cell type and inhibit
CD4+, CD8+, and NK, and promove tumor progression. Tumor
cells produce: PGE, COX, IL-6, VEGF, and other factors that recruit
MDSCs, TAMS, and Tregs, induce defective DCs, and induce an
immune suppressive microenvironment.
leukocytes that inhibit immunity response to cancer. We also
specify some of the potential strategies aimed to alter cancer
associated inflammation-immunity that are focused on the
components of the tumor microenvironment.
2. Immunosystem in the Prostate Gland
An immune response in the prostate has been reported, and
it is primarily cell-mediated [8].The greatest concentration is
in the stroma with a small but significant number of intraep-
ithelial cells. The lymphocytes are chiefly T cells (CD45RO+)
in both stromal and intraepithelial compartments. Stromal T
cells are mainly CD4+ helper/inducer cells, whereas intraep-
ithelial cells are CD8+ cytotoxic/suppressor. The abundance
of CD8+ suggests that cytotoxic T cells are the first line of
defense against luminal foreign agents. CD4+ T cells can have
different fates and are classified according to their cytokine
profile: T helper (Th)-1 and T helper (Th)-2.Th1 express T-bet
and produce interferon (IFN)-𝛾;Th2 express Gata-3 and pro-
duce IL-4 [9]. Tregs are CD4+ lineagewith essential immuno-
suppressive functions that often express transcription factor
like Forkhead box P3 (FoxP3+). Other T cells selectively
produce IL-17 and the transcription factor ROR𝛾t (Th17), and
finally newer T cells are identified and they are defined based
on their cytokine production: Th9 andTh22 cells.
As helper cells can change their phenotype, it has become
important to determine which T cells are more present in
inflammatory lesions of prostate from BPH until carcinoma.
In fact, an immune response is stimulated in PCa, as shown
also by histological data revealing the presence of CD4+ T
cells, CD8+ T cells, natural killer (NK) cells, dendritic cells
(DC), and macrophages within tumors. Furthermore, it has
been reported that a dense infiltration of lymphocytes is cor-
related with longer patient survival and that high grade pro-
static adenocarcinomas have significantly less infiltration of
T cells andmacrophages as compared to benign nodular pro-
static hyperplasia [10–13], suggesting that tumor progression
may be associated with alterations in cell-mediated immune
responses. On the contrary, [14] an increased inflammatory
cell infiltrate within the tumor is associated with an increased
risk of tumor recurrence. In some reports the presence of
CD4+ T cells infiltrate is related with poor cancer survival in
patients with PCa, probably due to an increase of Tregs. So far
it seems the presence of tumor associatedmacrophage (TAM)
and Tregs correlate with a poorer prognosis [4, 12]. A cross-
talk between these cells could promote synergy and amplify
the immune suppressive effects of individual cell population
[15].
2.1. Regulatory T Cells. CD4+CD25+ Tregs represent the
major Treg population in the immune system [16] and are
essential to maintain peripheral self-tolerance and avoid
autoimmunity. They are also responsible of limiting tissue
damage during ongoing and resolving immune responses [17,
18]. Expression of Foxp3+ generally identifies natural, thymus
derived Treg cells (nTregs) and may or may not be expressed
in inducible Tregs (iTregs) [19–21]. Foxp3+Tregs were
detected in the peripheral blood and tumor tissue in many
cancer patients suggesting their contribution to the reduction
of the antitumor immune response [22]. The recruitment of
Tregs (natural or induced) into tumors likely involves com-
plex, multistep processes not yet completely defined [22, 23].
Tregs generally contribute to decreasing immunity during
tumor development and progression, leading to poor out-
comes in cancer patients [24, 25]. Likewise a relative enrich-
ment of Tregs has been detected in prostate tissue and from
peripheral blood of PCa patients compared to normal donors
[26]. A significant association has been shown between
the number of Tregs and poor prognosis in PCa [27, 28].
Moreover Tregs level decreases after androgen ablation and
is elevated in the peripheral blood of patients with metastatic
castration-resistant prostate cancer (mCRPC) [26, 28–30].
The mechanisms of suppression mediated by Tregs
include cytotoxic T-lymphocytes-associated protein (CTLA)-
4, programmed death-ligand (PD-L)-1, lymphocyte-activa-
tion gene (LAG)-3, neuropilin (Nrp)-1, and CD39/73 expres-
sion [31].
2.2. Myeloid-Derived Suppressor Cells. MDSCs are elevated
at the tumor site, as well as in the peripheral blood of
cancer patients and a correlation between tumor-MDSCs
and patients survival has been described [32]. MDSCs are
a heterogeneous cell population characterized by the ability
to suppress T cells and NK cells functions. They consist
of myeloid progenitor cells and immature myeloid cells
(IMC). IMCs with a phenotype as MDSCs are contin-
ually generated in the bone marrow of healthy individ-
uals and differentiate into mature myeloid cells without
causing detectable immunosuppression [33]. Some patho-
logical conditions, such as acute or chronic infections,
trauma or sepsis, and cancer, prevent the differentiation
and MDSCs exhibiting immunosuppressive functions derive
[34, 35]. Until now two main MDSC populations have
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been characterized primarily in mice: polymorphonuclear
and monocytic MDSC. These cells share some characteris-
tics but have also many different markers that complicate
their studies and lead to controversial results. Nevertheless,
there is a growing consensus to define human MDSCs
as CD11b+CD33+HLA-DRlow/−Lin−. Within this population,
the CD14+CD15low/− MDSCs share characteristics with
murine M-MDSCs, while CD14−CD15+MDSCs resemble
murine G-MDSCs [36]. Several different factors, including
cyclooxygenase (COX)-2, prostaglandins (PGE), stem-cell
factor (SCF), Macrophage-Colony Stimulating Factor (M-
CSF), IL-6, granulocyte/macrophage CSF (GM-CSF), and
vascular endothelial growth factor (VEGF), induce expansion
and activation of MDSCs. These factors are also produced by
tumor cells and promote the expansion of MDSCs through
the stimulation of myelopoiesis and the inhibition of the
differentiation in mature myeloid cells. In addition other
signals are necessary to MDSCs activation, including IFN-𝛾,
ligands for Toll-like receptors (TLRs), IL-4, IL-13, andTGF-𝛽,
produced mainly by activated T cells and tumor stromal cells
after induction by different bacterial and viral products, or as
a result of tumor-cell death [33].
The immunosuppressive activities of MDSCs are medi-
ated by a variety of mechanisms. One mechanism consists in
the depletion of essential nutrients, especially L-Arg,metabo-
lized by arginase 1 and iNOS highly expressed inMDSCs.The
depletion of Arg inhibits T-cell proliferation by decreasing
their expression of CD3 𝜁-chain and preventing upregulation
of the expression of the cell cycle regulator, cyclin D3 [33,
37, 38]. Another mechanism is the generation of oxidative
stress caused by the production of reactive oxygen species
(ROS) and reactive nitrogen species by MDSCs, able to
produce several molecular blocks in T cells, ranging from
the loss of TCR 𝜁-chain expression and interference with
IL-2 receptor signaling [33, 39]. MDSCs also disrupt T cell
migration to lymphnodes by releasingADAM17which down
regulates L-selectin and prevents the homing receptor on T
cells [40]. At last, MDSCs promote the recruitment and the
expansion of Tregs by the production of IL-10, TGF-𝛼, IFN-
𝛾, and by CD40–CD40L interactions [41, 42]. In addition
MDSCs enhance tumor growth by promoting angiogenesis
[43], inducing tumor invasion and metastasis, and activating
the protective pathways of tumor cells from chemotherapy-
induced apoptosis [15, 33, 42].
Monocytic MDSCs have been detected elevated in the
peripheral blood of patients with PCa and the level of
MDSCs correlated with other negative prognostic factors for
metastatic PCa, such as lactate dehydrogenase, alkaline phos-
phatase, PSA, and anemia [44]. It has also been described that
CD14+HLA-DRlow/− monocytes isolated from PCa patients
expressed high level of IL-10, inhibited autologous T cell
proliferationmore effectively than (CD14+HLA-DR+) mono-
cytes from healthy individuals, and were defective in their
ability to differentiate into phenotypically mature DCs [45].
2.3. Macrophages. Macrophages play a basic role that pro-
mote host survival by regulating adaptive immunity, inducing
wound healing and eliminating infectious agents [46]. Their
precursor cells, monocytes, after extravasation into target
tissues differentiate to mature macrophages and polarize
in response to microenvironment. Each polarized macro-
phage displays a differential expression profile of cytokines,
enzymes, and cell-surface markers and they have been clas-
sified into two subsets. The classical M1, activated by IFN-𝛾
and lipopolysaccharide (LPS), are characterized by their high
expression of IL-12 and low expression of IL-10; the alterna-
tive M2, that are activated by IL-4, IL-13, IL-10, and glucocor-
ticoid hormones, produce high levels of IL-10 and low levels
of IL-12 [47, 48]. The role of macrophage in tumor devel-
opment has been controversial. Even though macrophage
surveillance mechanisms are essential for preventing the
growth of transformed cells, activated macrophages con-
tribute to early development of neoplasm through the free
radicals production. Furthermore tumor microenvironment
strongly polarizes macrophages towards a M2-like phe-
notype, the so-called TAMs, which facilitate tumor pro-
gression via both immunological and nonimmunological
mechanisms. In fact in tumor microenvironment, molecules
such as chemokines (CCL-2), cytokines (VEGF and M-
CSF), and hypoxia promote monocytes recruitment as well
as macrophages survival. TAMs expression correlates with
tumor growth [49]. Often the same factors inhibit the
differentiation of DCs. In turn, the recruited macrophages
provide a transcriptional program, activated throughNuclear
factor (NF-kB) and hypoxia-inducible transcription factors
(HIF)-1, which support tumor progression and metastasis
[4, 50, 51].
For many years a strict correlation between an increased
number of macrophages and a poor prognosis has been
described for many different tumors. TAMs are also a signi-
ficant component of the inflammatory infiltrates in PCa.
The detection of high density of M2 in both epithelial and
stromal compartments was statistically associated to poorer
prognosis [52, 53]. Moreover increased TAMs levels in bio-
psy are predictive of worse recurrence free survival in men
treated with primary androgen deprivation therapy. An
inverse correlation between total macrophage density and
time to recurrence has also been reported from different
analysis [54, 55].
2.4. Dendritic Cells. DCs are professional antigen-presenting
cells (APC), which are critical to initiate innate and adaptive
immune responses against pathogens and tumor cells, and
because these cells orchestrate a large repertoire in T cell
activation representing also a good tool forDCs-based cancer
vaccination strategies [56].
DCs are terminal differentiated myeloid cells that are
specialized in antigen processing and presentation. These
cells differentiate in the bone marrow from various progen-
itors. In human, monocytes represent the major precursors
of DCs. The differentiation leads to two major subsets of
DCs, conventional DCs (cDCs), and plasmacytoid DCs
(pDCs). They show different morphologies, markers, and
functions. Pathogen-associated molecular patterns (PAMPs)
and damage-associated molecular patterns (DAMPs) induce
different pathway of differentiation in DCs [57].The different
pathways of differentiation define the fate of DCs and their
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interaction with lymphocytes. In fact activated DCs produce
a different setting of costimulatory molecules and cytokines
inducing such contrasting states as immunity and tolerance.
DCs after capturing and processing antigens present them
to T cells through MHC and, by controlling Th1, mediate
a resistance to intracellular microbes, by Th2 a defense to
helminthes, by Th17 through IL-17 organize phagocytes at
body surface to resist extracellular bacilli. Alternatively, DCs
induce Tregs and cause tolerance. Maturing DCs also express
more IL-15 and activate inflammation and NK [57].
DCs maturation is induced by tumor derived molecules,
such as heat shock proteins (HPS) and high mobility-
group box- (HMGB-) 1 protein, as well as proinflammatory
cytokines produced by various tumor-infiltrating immune
cells. Matured DCs have different tumoricidal activities often
mediate by IFNproduction.DCs activate T cells andNKcells,
both these cells have cytotoxic activity against tumors. DCs
induce apoptosis and antiangiogenesis pathways via signaling
through IFN [58]. Alternatively tumor may perturb this pro-
cess by inducing the accumulation of immature DCs [33, 59].
The contact tumor-DCs or tumor-derived factors may affect
DCs maturation and function. It has been demonstrated that
tumor induces apoptosis or alters differentiation ofDCaswell
as accumulation of immature cells with inhibitory function
could impair immune responses [59, 60]. Defective DCs
function has been found in many patients with a variety of
cancers [61].
Some authors have detected in prostate carcinoma a
significant correlation between low numbers of CD1a+ cells
(characterized DCs) and a high Gleason score, by contrast;
DCs have been found elevated in low risk cancer [62]. Patients
that suffer from metastatic PCa showed fewer circulating
myeloid DCs than their age-matched controls [63]. These
results indicate that in PCa patients monocytes do not
develop into myeloid DCs as efficiently as they do in healthy
individuals. This idea is also supported by observations that
serum from PCa patients inhibited monocyte differentiation
into DCs and that the degree of inhibition correlated with
higher PSA levels [64].
3. Immunotherapy in Prostate Cancer:
Clinical Data
Cancer immunotherapy has recently been introduced into
the therapeutic field of metastatic PCa andmCPRC.The goal
of immunotherapy is to harness the capabilities of immune
system to effectively recognize and kill transformed cells
whilst sparing healthy tissues [65, 66]. Over the past decade,
strong evidences that PCa is immunogenic have emerged,
which showed the rationale for using immune-based thera-
pies for the treatment of metastatic PCa. This is confirmed
by the support of the presence of several tumor associated
antigens in the prostate; which include the PSA, prostatic
acid phosphatase (PAP), prostate specific membrane antigen
(PSMA), prostate stem cell antigen (PSCA), mucin-1 (MUC-
1), and the cancer testis antigen NY-ESO-1. As already
mentioned, histological data revealed the presence of CD4+,
CD8+ T cells, NK cells, DCs, andmacrophages within tumors
[7, 11]. Early studies reported that high grade PCa have
significantly less infiltration of T cells, suggesting that tumor
progression could be associated with defects in cell-mediated
immune responses. A high prevalence of Tregs within tumors
is associated with more lethal PCa, suggesting that thera-
peutic blockade of these cells may induce beneficial clinical
response. Another recent observation consists in a reduced
infiltration of CD68+ macrophages that is associated with
lymph node positivity and higher clinical stage. Increased
NK infiltrate within tumors was also found to be associated
with a lower risk of progression providing evidence that these
innate immune cells may have a protective role against PCa.
Four of the current immunologic therapeutic approaches
with particular relevance to mCPRC are discussed in more
detail in this section of the review (Table 1).
Sipuleucel-T is an autologous active cellular immune-
therapy product that stimulates a T-cell immune response
against cancer cells [65]. It is the first documented immuno-
therapy to prolong survival in mCRPC demonstrated in a
phase III trial [67]. Autologous peripheral blood mononu-
clear cells (PBMCs) of patient are incubated ex vivo for 36/48
hours with a fusion protein (PA2024) of PAP and GM-CSF
[68]. After about 40 hours, the fusion protein is washed out
and the product is reinfused into the patient. This product
contains at least 5 × 107 autologous activated CD54+ DCs and
a variable number of T cells, B cells, NK cells, and others
[74]. Sipuleucel-T immunotherapy targets cells positive for
PAP, a secreted glycoprotein enzyme that is expressed in
95% of prostate tissue and PCa [75]. Phase I/II clinical
trials have shown that Sipuleucel-T is well-tolerated and
the patients developed an appreciable antigen specific T-cell
responses and antibodies against the fusion protein after the
treatment [69, 70]. Actually three phase III clinical trials have
been completed and showed promising findings of this DCs
based vaccine. The two first studies compared patients with
asymptomatic mCRPC assigned to placebo or Sipuleucel-T.
There was no difference in time to progression but there was
a significant increase of overall median survival (25.9 months
versus 21.4 and 19.0 months versus 15.7) [76, 77]. A third
phase III clinical trial known as Immunotherapy for Prostate
Adenocarcinoma Treatment (IMPACT) trial showed a 4.1
months improvement inmedianOS and at 36-month interval
the survival rate was 31.7% for treated patients compared to
23.0% for cases treated with placebo [67, 78].
Ipilimumab is a fully human IgG1 monoclonal antibody
that Bind to and blocks the activity of CTLA-4. CTLA-4
has been shown to be potent negative T cells responses and
is upregulated following T-cell stimulation to attenuate the
response. CTLA-4 is also constitutively expressed on Tregs
and mediates their immune suppressive effects [71]. Ipili-
mumab was approved by the FDA on 2011 for the treatment
of advanced melanoma and is currently being trialled for
the treatment of nonsmall cell lung cancer, metastatic renal
cell cancer, and ovarian cancer. Regarding PCa, preclinical
studies that combine ipilimumab with standard anticancer
therapies are giving encouraging results. Synergic antitumor
activity between radiotherapy and CTLA-4 blockade has
emerged in a phase I, II study. In this study ipilimumab given
alone in a dose escalation or in addition to a single fraction of
radiation each day before starting the treatment, resulted in
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Table 1: Current immunologic therapeutic approaches in PCa.
Therapy Molecule Mechanism of action Clinical trials [Ref.]
Sipuleucel-T (Provenge) Autologous cellular immune-therapy Stimulates a T cell immune responseagainst cancer cells (+ for PAP)
Phases I-II: [61]
Phase II: [63–65]
Ipilimumab (Yervoy) IgG1 Human monoclonal antibody Blocks the activity of CTLA-4 and Tregexpression
Phases I-II: [67]
Phase III: [68]
Tasquinimod Oral quinolone-3-carboxamide Antitumor action through inhibition ofangiogenesis and immunomodulation Phase III: [69, 70]
Prostvac-VF Vector based vaccing
A combination of two viral particles,
vaccinia, and fowlpox that infect the APC
cells promoting an immune response
against PSA expressing cells
Phase II: [71]
GVAX
Granulocyte-macrophage
colony-stimulating factor (GM-CSF)
gene-transfected tumor cell vaccine
Evocation of a strong immunoreaction by
antigens expressed on human prostate
cell lines modified by GM-CSF
Phase III: [72, 73]
some very significant PSA declines [72]. There are currently
phase III trials that are evaluating the effect of ipilimumab
in patients with metastases who received or not docetaxel.
A primary analysis showed no significant difference between
the ipilimumab group and the placebo group in terms of
overall survival. However, ipilimumab seems to be associated
with better survival than placebo [73].
Tasquinimod, a quinoline-3-carboxamide analog, is in
clinical development for treatment of prostate cancer and
other solid tumors. In a placebo-controlled, phase II random-
ized trial, tasquinimod doubled the median progression-free
survival (PFS) period and prolonged survival of patients with
metastatic CRPC [79, 80]. A phase III clinical trial to test
the effect of tasquinimod in the same patients population
is ongoing (NCT01234311). Tasquinimod has been shown
to inhibit prostate cancer growth and metastasis in animal
models [81, 82]. Results from these studies have suggested
that the antiangiogenic property of this molecule may be
responsible for its antitumor activity, since tumor growth
inhibition was associated with reduced microvasculature
density, increased expression and secretion of the angio-
genesis inhibitor thrombospondin-1 (TSP-1), and downreg-
ulation of VEGF and HIF-1𝛼 [83]. More recent data have
suggested that tasquinimod may affect HIF by interfering
with histone deacetylase 4 (HDAC 4) [84]. However, in an
orthotopic, metastatic prostate cancer model, tasquinimod
reduced the metastatic rate without affecting microvessel
density in the primary tumor. Therefore, mechanisms other
than impairing angiogenesis may play an important role in
the antitumor and antimetastasis activities of tasquinimod.
At this regard, S100A9 has been identified as a potential
target of tasquinimod. S100A9 interacts with proinflamma-
tory receptors: TLR4 and receptor of advanced glycation end
products (RAGE). These receptors are expressed on MDSC,
macrophages, DCs, and endothelial cells. S100A9 regulates
the accumulation of MDSCs and inhibits DCs differentiation
leading to immune response suppression [85].
Viral vectors are attractive for use in cancer immunother-
apies as they can mimic natural infection and lead to the
induction of immune response against the tumor antigen that
they encode.
Prostvac-VF (viral-based vaccine) is a recombinant viral
vaccine currently being trialled as an immunotherapy for
PCa. Prostat-VF (TRICOM or PSA TRICOM) is based on a
combination of two viral particles, vaccinia which is a potent
immunologic priming agent, followed by fowlpox which is
minimally or noncross reactive with vaccinia that is used as a
boosting agent. Both recombinant viruses are engineered to
encode the entire PSA gene with a modified agonist epitope
and three costimulatory proteins B7-1 (facilitates T cell
activation), lymphocyte function/associated antigen 3 (LFA-
3; CD58), and intercellular adhesion molecule-1 (ICAM-1;
CD54). The rationale behind this approach is that the virus
will directly infect the APCs or somatic cells at the site
of injection, leading to cell death and subsequent uptake
of cellular debris containing PSA by the APCs [86]. The
transduced APCs or antigen-loaded APCs upon interaction
with CD4+ and CD8+T cells will effectively promote the T-
cell mediated immune responses that destroy PSA expressing
cells. Prostvac-VF/TRICOM was evaluated in a randomized
phase II clinical trial in men with mCPRC. Comparing men
who received Prostvac-VF and GM-CSF and men received
empty vector plus placebo, this study showed positive results
in median OS with a difference of eight months between
treated groups. Medians OS in the control group was 16.6
versus 25.1 months in PROSTAVAC group [87]. There is also
currently a global phase III trial that included 1200 men
with mCRPC treated with PROSTAVAC or placebo that will
determine the overall survival.
GVAX, granulocyte-macrophage colony-stimulating fac-
tor tumor cell vaccine, represents the whole-cell based
immunotherapy. Whole autologous or allogeneic tumor cells
as source of immunogens are genetically modified to express
GM-CSF. GM-CSF enhances immune responses through
the recruitment and activation of DCs at the injection site,
necessary to process and present antigens, a critical step
in the induction of an optimal immune response to any
immunotherapy [88]. Because the small number of cells that
can be obtained from surgically removed tumors limits autol-
ogous approach, GVAX for PCa is composed of two human
prostate cell lines, LANCaP (androgen sensitive derived from
a lymph node metastasis) and PC3 (androgen insensitive
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derived from bonemetastasis) as antigens source, transfected
with GM-CSF, and then irradiated for safety [89, 90]. Phase
I/II trials were performed: patients with hormone-refractory
prostate cancer (HRPC), chemotherapy-naive, received an
intradermal priming vaccination with GVAX-PCa (5 × 108
cells, half quantity of each cell line) followed by 12 weekly
boost for 6 months [89] or ranged doses (1 × 108 cells to 5
× 108 cells) [90]. This immunotherapy resulted well tolerated
and immunogenic for many of metastatic HRPC patients in
terms of dose and time treatment with an encouraging OS
rates.These data supported to initiation of two phase III trials
to confirm the survival benefits.The first phase III study, Vac-
cine Immunotherapy with Allogeneic Prostate Cancer Cell
Lines (VITAL)-1, was a phase III trial designed to compare
GVAX to docetaxel plus prednisone in asymptomatic CRPC
[91, 92]. VITAL-2 was conducted in symptomatic CRPC [91,
92].TheVITAL-2 studywas terminated early due to increased
deaths in the vaccine arm. Not long after, the VITAL-1 study
was terminated based on a futility analysis of less than a 30%
chance of meeting its end point [91].
The failure of GVAX immunotherapy to demonstrate
clinical benefit in PCa has urged some considerations. The
critical points are the lack of placebo arm and dose lev-
els and the timing of chemotherapy was not conducted.
Moreover the effects of immunotherapy may need a longer
time than conventional therapy; other biological markers
may be necessary to determine the effect of immunotherapy
and finally the development of immunosuppression espe-
cially in metastatic disease that may require a different
approach [91]. Emerging data suggest that this effect may
be at least partially obviated by combining immunotherapy
with immune checkpoint antagonist or immune agonist
[91]. In this regard, a combined treatment with GVAX and
ipilimumab in patients with metastatic CRPC was trialled.
The tolerable dose and the safety profile resulted in a phase I
study warrant further research [92]. In addition results from
a trial including mCRPC patients treated with fixed initial
doses of ipilimumab and PSA-Tricom vaccine have shown a
raise of the median overall survival [93].
4. Conclusions
Immunotherapies have gained momentum in cancer ther-
apeutics following the recent approvals of drugs for the
treatment of prostate cancer andmelanoma. Immunotherapy
has the potential to mount an ongoing, dynamic immune
response that can kill tumor cells for an extended time after
the conventional therapy has been administered. Despite
these clinical advances, further studies are still necessary to
increase the understanding of the responses to these types of
therapy and of the optimal management of different subset
of patients. The most promising immune-based treatments
are monoclonal antibodies that act as checkpoint inhibitors
(e.g., ipilimumab and nivolumab), adoptive cell therapy (e.g.,
T cells expressing chimeric antigen receptors), and vaccines
(e.g., Sipuleucel-T).
It is reasonable that a single immune therapeutic agent
is unlikely to be clinically effective especially in metastatic
patients and combing vaccines with immune check-point
inhibitors can reorganize the immunological network to
mount an immune response against the prostate cancer anti-
gens.
Many trials are also ongoing to define the effects of
immune therapy with established treatments: androgen
deprivation therapy (ADT) and chemotherapy (CT) or radio-
therapy (RT) [94]. As mentioned above, studies about
possible combine immunotherapies are ongoing to better
establish the safety and toxicity other than the efficacy of such
treatments. In our opinion, identifying doses and timing and
the sequences of combined treatments are crucial to gain a
synergic effect.
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